BioPharmSignal logoBioPharmSignal

Biotech News

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Arbutus (ABUS)ArbutusEarnings

Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery technology represents significant outcome for Arbutus and Genevant Two additional patients from Phase

Related news

ABUSArbutus2026-08-12 11:30 EST

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ABUSArbutus2026-05-13 11:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

BNTXBioNTech2026-03-10 10:45 EST

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

SCYXSCYNEXIS2026-08-10 20:30 EST

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BRNSBarinthus Biotherapeutics2026-08-06 12:00 EST

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

SCYXSCYNEXIS2026-05-11 20:23 EST

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

BRNSBarinthus Biotherapeutics2026-04-30 11:30 EST

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

PHARPharming Group2026-07-30 05:00 EST

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

ANTXAN2 Therapeutics2026-03-17 20:00 EST

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

View all latest news

Arbutus

Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins,...

Recent company news

ABUSArbutus2026-08-12 11:30 EST

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ABUSArbutus2026-07-16 11:30 EST

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

ABUSArbutus2026-05-13 11:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

ABUSArbutus2026-04-15 11:30 EST

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

ABUSArbutus2026-03-23 11:30 EST

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Stock data

Close
4.71 USD
Market cap
841.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States